{
  "description": "The researcher asks to compare eligibility criteria across three multiple\u2011myeloma trials. The assistant parses each trial\u2019s free\u2011text criteria with the eligibility_parser tool, receives structured JSON for each, and then presents a side\u2011by\u2011side comparison highlighting common and differing requirements.",
  "messages": [
    {
      "role": "system",
      "content": "You are TrialMatchAI, an AI\u2011enhanced clinical trial recruiter. You can parse free\u2011text eligibility criteria, query EMR data, send secure messages, capture consent, and schedule meetings. Always keep audit logs and respect patient privacy."
    },
    {
      "role": "user",
      "content": "I\u2019m a researcher studying multiple\u2011myeloma. I have three similar trials (Trial A, Trial B, and Trial C) and I want to compare their inclusion and exclusion criteria side\u2011by\u2011side. Here are the eligibility texts:\n\n**Trial A**\nInclusion: Age 18\u201175, diagnosed with multiple\u2011myeloma, ECOG \u22642, measurable disease, prior therapy \u22642 lines. Exclusion: Prior stem cell transplant, active hepatitis B or C, uncontrolled hypertension.\n\n**Trial B**\nInclusion: Age 21\u201180, confirmed multiple\u2011myeloma, ECOG \u22641, measurable disease, no prior exposure to immunomodulatory drugs. Exclusion: Prior autologous stem cell transplant, active infection, significant cardiac disease.\n\n**Trial C**\nInclusion: Age \u226518, multiple\u2011myeloma refractory to at least one line, ECOG \u22642, measurable disease, adequate organ function. Exclusion: Prior allogeneic transplant, active CNS involvement, uncontrolled diabetes."
    },
    {
      "role": "assistant",
      "content": "Sure, I\u2019ll transform each trial\u2019s free\u2011text criteria into a structured JSON schema so we can compare them easily.",
      "tool_calls": [
        {
          "id": "eligibility_parser_1a2b3c",
          "name": "eligibility_parser",
          "arguments": {
            "eligibility_text": "Inclusion: Age 18\u201175, diagnosed with multiple\u2011myeloma, ECOG \u22642, measurable disease, prior therapy \u22642 lines. Exclusion: Prior stem cell transplant, active hepatitis B or C, uncontrolled hypertension."
          }
        },
        {
          "id": "eligibility_parser_4d5e6f",
          "name": "eligibility_parser",
          "arguments": {
            "eligibility_text": "Inclusion: Age 21\u201180, confirmed multiple\u2011myeloma, ECOG \u22641, measurable disease, no prior exposure to immunomodulatory drugs. Exclusion: Prior autologous stem cell transplant, active infection, significant cardiac disease."
          }
        },
        {
          "id": "eligibility_parser_7g8h9i",
          "name": "eligibility_parser",
          "arguments": {
            "eligibility_text": "Inclusion: Age \u226518, multiple\u2011myeloma refractory to at least one line, ECOG \u22642, measurable disease, adequate organ function. Exclusion: Prior allogeneic transplant, active CNS involvement, uncontrolled diabetes."
          }
        }
      ]
    },
    {
      "role": "tool",
      "tool_call_id": "eligibility_parser_1a2b3c",
      "content": "{\n  \"trial\": \"A\",\n  \"inclusion\": {\n    \"age_min\": 18,\n    \"age_max\": 75,\n    \"diagnosis\": \"multiple-myeloma\",\n    \"ecog_max\": 2,\n    \"measurable_disease\": true,\n    \"prior_therapy_max_lines\": 2\n  },\n  \"exclusion\": {\n    \"prior_stem_cell_transplant\": true,\n    \"active_hepatitis\": [\"B\", \"C\"],\n    \"uncontrolled_hypertension\": true\n  }\n}"
    },
    {
      "role": "tool",
      "tool_call_id": "eligibility_parser_4d5e6f",
      "content": "{\n  \"trial\": \"B\",\n  \"inclusion\": {\n    \"age_min\": 21,\n    \"age_max\": 80,\n    \"diagnosis\": \"multiple-myeloma\",\n    \"ecog_max\": 1,\n    \"measurable_disease\": true,\n    \"no_prior_immunomodulatory\": true\n  },\n  \"exclusion\": {\n    \"prior_autologous_stem_cell_transplant\": true,\n    \"active_infection\": true,\n    \"significant_cardiac_disease\": true\n  }\n}"
    },
    {
      "role": "tool",
      "tool_call_id": "eligibility_parser_7g8h9i",
      "content": "{\n  \"trial\": \"C\",\n  \"inclusion\": {\n    \"age_min\": 18,\n    \"age_max\": null,\n    \"diagnosis\": \"multiple-myeloma\",\n    \"ecog_max\": 2,\n    \"measurable_disease\": true,\n    \"refractory_to_at_least_one_line\": true,\n    \"adequate_organ_function\": true\n  },\n  \"exclusion\": {\n    \"prior_allogeneic_transplant\": true,\n    \"active_cns_involvement\": true,\n    \"uncontrolled_diabetes\": true\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "Here is a side\u2011by\u2011side comparison of the three trials\u2019 structured eligibility criteria:\n\n| Criterion | Trial A | Trial B | Trial C |\n|---|---|---|---|\n| **Age** | 18\u201175 | 21\u201180 | \u226518 (no upper limit) |\n| **Diagnosis** | Multiple\u2011myeloma | Multiple\u2011myeloma | Multiple\u2011myeloma |\n| **ECOG \u2264** | 2 | 1 | 2 |\n| **Measurable disease** | \u2705 | \u2705 | \u2705 |\n| **Prior therapy lines** | \u22642 lines | No prior immunomodulatory drugs | Refractory to \u22651 line |\n| **Organ function** | \u2013 | \u2013 | Adequate organ function required |\n| **Exclusion \u2013 Stem cell transplant** | Any prior transplant | Prior autologous transplant | Prior allogeneic transplant |\n| **Exclusion \u2013 Infection** | Active hepatitis B/C | Active infection (any) | \u2013 |\n| **Exclusion \u2013 Cardiovascular** | Uncontrolled hypertension | Significant cardiac disease | \u2013 |\n| **Exclusion \u2013 CNS** | \u2013 | \u2013 | Active CNS involvement |\n| **Exclusion \u2013 Metabolic** | \u2013 | \u2013 | Uncontrolled diabetes |\n\n**Key similarities**:\n- All three require a confirmed diagnosis of multiple\u2011myeloma and measurable disease.\n- ECOG performance status is required for all (\u22642 for A and C, stricter \u22641 for B).\n- All exclude patients with a prior stem\u2011cell transplant, though the type differs.\n\n**Key differences**:\n- Age ranges vary; Trial C has the broadest age eligibility.\n- Trial B uniquely forbids any prior immunomodulatory therapy, while Trial A limits total prior lines to two.\n- Trial C adds a refractory\u2011to\u2011treatment requirement and mandates adequate organ function, which are not explicitly stated in A or B.\n- Specific comorbidity exclusions differ (hepatic vs. cardiac vs. CNS vs. metabolic).\n\nLet me know if you\u2019d like to:\n1. Search your EMR for patients who meet the criteria of any (or all) of these trials, or\n2. Generate a concise eligibility summary document for each trial to share with your study team, or\n3. Anything else you have in mind.",
      "tool_calls": []
    }
  ]
}